XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
US Stock MarketDetailed Quotes
PTN Palatin Technologies
- 1.0000
- -0.0600-5.66%
Close Feb 14 16:00 ET
- 1.0000
- 0.00000.00%
Post 20:01 ET
26.01MMarket Cap-0.65P/E (TTM)
1.0700High0.9883Low775.65KVolume1.0400Open1.0600Pre Close787.42KTurnover3.24%Turnover RatioLossP/E (Static)26.01MShares3.992952wk High-4.08P/B23.97MFloat Cap0.680052wk Low--Dividend TTM23.97MShs Float2687.5000Historical High--Div YieldTTM7.71%Amplitude0.6800Historical Low1.0150Avg Price1Lot Size
Trending Stocks
Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio?
Moo Live
Jan 30 03:25
FOMC Press Conference, January 29, 2025
Palatin Technologies Stock Forum
Palatin Slashes Quarterly Losses 70%, Obesity Drug Trial Results Imminent
loading up
👀
PR Newswire· 8 mins ago
Last Patient / Last Visit CompletedTopline Data Readout Expected Later This Quarter
Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
Thursday, 6th February at 7:30 am
• Last Patient / Last Visit Completed
• Topline Data Readout Expected Later This Quarter
CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced t...
Obesity Treatment Breakthrough? Palatin's Novel GLP-1 Combo Trial Wraps Up With Massive Patient Interest
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
7. I DO NOT give buy or sell advice
8. COH (cash on hand); AH (after hours): RTH (regular trading hours)
$Aadi Biosciences (AADI.US)$ PR AH 12/...
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy
Thursday, 19th December at 7:30 am
• Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy
• Demonstrated efficacy at 6 months
◦ 71% percent of patients achieved a >30% reduction in the urine protein to creatinine ratio (UP/Cr)
◦ 71% of patients achieved improved or stab...
No comment yet